New breast imaging technology targets hard-to-dete... (found by mammography or physical exam wh...)

New breast imaging technology targets hard-to-detect cancers

Date:12/2/2008

found by mammography or physical exam, who had undergone BSGI to determine if additional lesions were present.

BSGI results showed an additional suspicious lesion missed by mammography and physical exam in 46 (29 percent) of the women. In 14 (36 percent) of the 39 women who underwent biopsy, the newly discovered lesions were cancerous.

"The data suggest that BSGI allows for the diagnosis of more and earlier breast cancers," Dr. Brem said.

Dr. Brem pointed out that BSGI is not meant to replace mammography, but to be used as an adjunct to mammography. "It is an excellent tool for locating difficult-to-detect cancers and for screening high-risk women who have normal mammograms and physical examination," she said.

'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma
2. EIN News Introduces Breast Cancer News Today; Website Offers Information on Risk Factors, Treatment, Drugs
3. HER2 levels may aid in treatment selection for metastatic breast cancer
4. New mammography technology effective in detecting breast cancer
5. Delays in radiation therapy lead to increased breast cancer recurrence
6. Radioactive Seed Rx Helps Women With Implants Fight Breast Cancer
7. Breast cancer in men: Mammography and sonography findings
8. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
9. Molecular Breast Imaging Proves Cost-Effective for Presurgical Planning in Patients with Breast Cancer
10. Molecular Breast Imaging Performs Better Than Ultrasound in Patients With Mammographic Abnormalities
11. Breast cancer treatment offers better outcome to women with implants

Post Your Comments:

(Date:11/9/2009)...na, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray ...ing developer, manufacturer and,marketer of medica...unaudited,financial results for the third quarter ...Highlights for Operations as of September 30, 2009...1 million, an increase of, 3.1% over the thi...

(Date:11/9/2009)...ks President Obama,s promise to not expand abortio... Bishops still concerned for poor, elderly ,, ...inal Francis George of Chicago, president of the U...d the November 7 decision of the U.S. House of Rep...oney from paying for elective abortions. ,, In...

(Date:11/9/2009)... Studying Genetic Variance Across the World is C... (Vocus) November 9, 2009 --...xtraordinarily valuable when analyzing and interpr...ics study that scanned the genomes of 4,000 peopl...rences, Drs. Chao Tian and Michael F. Seldin of th...

(Date:11/9/2009)...new cells regained sexual function, study says,...Researchers were able to restore sexual function t...le tissue in the lab and implanting it, a new stud...ys off, researchers say the technique could one da...men. , "We were able to show the tissue was abl...

(Date:11/9/2009)... Course, to be Offered in April 2010, Provides F... Cambridge, MA (Vocus) November 9,...an Rights (PHR) first inspected a suspected mass ...d he would need a team of experts to help interpre...perly was a key first step in securing evidence of...

[0] Mindray Announces Third Quarter 2009 Financial Results [0] Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly [0] News from the November/December Issue of Molecular Medicine [0] Scientists Grow New Penile Tissue in the Lab [2] Physicians for Human Rights Offers Training in Crime Scene Documentation

...N.J., Dec. 12 Alfacell Corporation (Nasdaq: AC...president, chief financial officer and corporate s...s of today. Mr. Kenyon will remain on the board o... Kenyon has accepted a full time position as execu...

...ass., Dec. 12 Millennium Research Group (MRG) ana...ished G lobal Markets for Hyaluronic Acid Viscos...fer extensive expertise on the recent FDA premarke...s available to comment on: , , , , ...

..., Dec. 12 Ogilvy Public Relations Worldwide (Ogi... announced today that it has been awarded a five-y...with the National Cancer Institute (NCI), Office o...,s life sciences consulting subsidiary, Feinstein ...

...hase 3 Program Expected to Begin in December - , ...rmaceuticals, a division of Wyeth (NYSE: WYE ), ...inical trial of neratinib (HKI-272) in women with ...the ErbB-2 receptor (also known as HER-2 or Neu). ...

...s not sure whether one causes the other, or one is...2 (HealthDay News) -- Adults who have panic disord...t attacks and heart disease, but not heart-related...than 347,000 adults without the condition. , Peopl...

...ec. 12 The Female Health Company (NYSE Alternex...Administration,s (FDA) Obstetrics and Gynecology D...at the company,s second-generation female condom, ...ondition that the FC2 Female Condom,s instructions...

Other Medicine News:Health News:Alfacell Announces Management Update 2 Health News:Alfacell Announces Management Update 3 Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2 Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4 Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5

Alfacell Announces Management Update Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer Panic Disorder Linked to Higher Risk of Heart Disease FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable

(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...

(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...

(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...

[0] Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress [0] American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009 [0] Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments

...E)--May 24, 2007 - Cyclacel,Pharmaceuticals, Inc. ... it will report results from a Phase I pharmacolog...available nucleoside analog,in patients with adva... at the American Society of Clinical Oncology,s (A... Details of the presentation,are as follows:, Abst...

... - HepaLife Technologies, Inc.,(OTCBB:HPLF) (FWB:H...ic presentation of its cell based PBS-1 technology... "Options for the,Control of Influenza VI Conferen...da., Entitled "High titer growth of human and avia...o cell line without the need for,exogenous proteas...

Other Medicine Technology:Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 2 Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 3 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting

EBI OsteoGen™-M (Mesh Cathode)

Interference Screws

...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...

PHANTOM SofThread Cannulated Interference Screws

Medicine Products:

EBI OsteoGen™-M (Mesh Cathode)Interference Screws SmartScrew ACL PHANTOM SofThread Cannulated Interference Screws

New breast imaging technology targets hard-to-dete...(found by mammography or physical exam wh...),Health